Tag: pharmaceutical products

LSL PHARMA GROUP ANNOUNCES THE COMPLETION OF EARLY REDEMPTION OF ALL 11% UNSECURED CONVERTIBLE DEBENTURES

BOUCHERVILLE, QC, Aug. 4, 2025 /CNW/ - LSL PHARMA GROUP INC. (TSXV: LSL) ("LSL Pharma" or the "Corporation"), a Canadian integrated pharmaceutical company, today announced...

Zenara Pharma Receives U.S. FDA Approval for First Generic of Sertraline Hydrochloride Capsules with 180-Day CGT Exclusivity

HYDERABAD, India, August 1, 2025 /PRNewswire/ -- Zenara Pharma Private Limited ("Zenara"), a Biophore company, today announced that it has received final approval from the U.S....

Zenara Pharma Receives U.S. FDA Approval for First Generic of Sertraline Hydrochloride Capsules with 180-Day CGT Exclusivity

HYDERABAD, India, July 31, 2025 /PRNewswire/ -- Zenara Pharma Private Limited ("Zenara"), a Biophore company, today announced that it has received final approval from the U.S....

Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil

MONTREAL, July 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with rituximab and lenalidomide for the treatment of adult patients with previously treated follicular lymphoma (FL). The supplemental application for the additional indication was selected for review under Project Orbis.

Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for Novel AhR Agonist Development

Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025:

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million

SHANGHAI, July 25, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and...

Abivax Announces Launch of Public Offering

Abivax Announces Launch of Public Offering

British Columbia Joins Other Provincial Public Drug Plans Now Reimbursing FOQUEST® on their Formulary for Attention Deficit Hyperactivity Disorder (ADHD)

TORONTO, July 23, 2025 /CNW/ - Elvium Life Sciences is pleased to announce the addition of FOQUEST® (methylphenidate hydrochloride controlled release capsules) to the British...

Neuraxpharm continues international expansion with launch of Neuraxpharm Australia

Avendran Naidu appointed Head of Commercial to lead new affiliate CNS specialist continues growth strategy outside Europe to commercialise CNS treatments, including Nuvigil® (armodafinil), Modavigil®...

Neuraxpharm continues international expansion with launch of Neuraxpharm Australia

Avendran Naidu appointed Head of Commercial to lead new affiliate CNS specialist continues growth strategy outside Europe to commercialise CNS treatments, including Nuvigil® (armodafinil), Modavigil®...

Astellas Announces a Partnership with the “Korea Institute of Startup and Entrepreneurship Development”, an Umbrella Organization of the “Ministry of SMEs and Startups”, a...

- Supporting Korean Startups' Drug Discovery Research and Global Expansion - - First Pharmaceutical Company from Japan to Actively Support the Operation of the Program...

Avicanna Announces Closing of Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS

Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™

Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025

Datavault AI Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Minister MacDonald concludes G7 Agriculture Ministers’ Meeting

SRAD Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Sportradar Group AG Class Action Lawsuit

LSL PHARMA GROUP ANNOUNCES THE COMPLETION OF EARLY REDEMPTION OF ALL 11% UNSECURED CONVERTIBLE DEBENTURES

Zenara Pharma Receives U.S. FDA Approval for First Generic of Sertraline Hydrochloride Capsules with 180-Day CGT Exclusivity

Zenara Pharma Receives U.S. FDA Approval for First Generic of Sertraline Hydrochloride Capsules with 180-Day CGT Exclusivity

Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil

Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for Novel AhR Agonist Development

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million

Abivax Announces Launch of Public Offering

British Columbia Joins Other Provincial Public Drug Plans Now Reimbursing FOQUEST® on their Formulary for Attention Deficit Hyperactivity Disorder (ADHD)

Neuraxpharm continues international expansion with launch of Neuraxpharm Australia

Neuraxpharm continues international expansion with launch of Neuraxpharm Australia

Astellas Announces a Partnership with the “Korea Institute of Startup and Entrepreneurship Development”, an Umbrella Organization of the “Ministry of SMEs and Startups”, a...

Avicanna Announces Closing of Non-Brokered Private Placement

Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us